GP73 is a potential marker for evaluating AIDS progression and antiretroviral therapy efficacy
GP73 is a potential marker for evaluating AIDS progression and antiretroviral therapy efficacy
复制标题
GP73是评估艾滋病进展和抗逆转录病毒治疗效果的潜在标志物。
DOI：
10.1007/s11033-013-2754-5
复制
发表时间：
2013-11-01
影响因子：
2.8
通讯作者：
Li, Xin
中科院分区：
文献类型：
--
作者：
Wei, Hongshan;Hao, Xiaohua;Li, Xin
高尔基体蛋白-73(GP73)在癌症和病毒感染中表达上调，但其在人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合征(AIDS)中的作用尚不确定。GP73被评估为艾滋病毒进展和艾滋病治疗疗效的生物标志物。从2009年5月至2012年6月，48名正在接受高效抗逆转录病毒治疗(HAART组)的HIV患者和18名预期在9个月内接受HAART的HIV患者(对照组)被纳入一项前瞻性的单中心队列研究。分别于基线、2周、1、3、6、9、12个月(HAART组)或间隔3个月(对照组)检测血中天冬氨酸氨基转移酶、丙氨酸氨基转移酶(ALT)、胆固醇、甘油三酯和总胆红素。用逆转录聚合酶链式反应(RT-PCR)检测血清HIV RNA水平(病毒载量)，用化学发光免疫试剂盒检测血清和外周血单个核细胞(PBMC)GP73浓度。血清gP_(73)浓度与HIV病毒载量(r=0.39，P<0.001)和CD_4~+T细胞计数(r=-0.501，P<0.001)分别呈显著正相关和负相关。在受试者操作特征(ROC)分析中，曲线下面积(AUC)为0.79(95%CI为0.66~0.92)。Gp73正确识别CD_4~+T细胞数为350‰的患者的敏感性和特异性分别为76.09%和75.0%，以ROC为界值为100.6 ng/m L。对于正在接受抗逆转录病毒治疗的HIV患者，GP73可能是一种潜在的生物标志物治疗效果，在艾滋病治疗中有用。
Golgi protein-73 (GP73) is upregulated in cancers and viral infections; however, its role in human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) remains undetermined. GP73 was evaluated as a biomarker of HIV progression and AIDS treatment efficacy. Forty-eight HIV patients (a parts per thousand currency sign350 CD4 + T cells/mu L) undergoing highly active antiretroviral therapy (HAART group) and 18 HIV patients expected to undergo HAART within 9 months (> 350 CD4 + T cells/mu L) (control group) were enrolled in a prospective, single center, cohort study from May 2009 to Jun 2012. Blood aspartate aminotransferase, alanine aminotransferase (ALT), cholesterol, triglycerides, and total bilirubin were assessed at baseline, 2 weeks, and 1, 3, 6, 9, and 12 months (HAART group) or 3 month intervals (control group). Serum HIV RNA level (viral load) was determined by reverse-transcriptase polymerase chain reaction (RT-PCR), and serum and peripheral blood mononuclear cell (PBMC) GP73 concentration were determined by chemiluminescent immunoassay kit and western blot, respectively. Significant positive and negative correlations in baseline serum GP73 concentration and HIV viral load (r = 0.39, P < 0.001) and CD4 + T cell count (r = -0.501, P < 0.001) were observed, respectively. In receiver operator characteristic (ROC) analysis, area under the curve (AUC) was 0.79 (95 % CI 0.66-0.92). The sensitivity and specificity of GP73 for correct identification of patients with a parts per thousand currency sign350 CD4 + T cells/mu L were 76.09 and 75.0 %, respectively, with an ROC-derived cut-off of 100.6 ng/mL. For HIV patients undergoing antiretroviral therapy, GP73 may be a potential biomarker treatment efficacy useful in AIDS management.